These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9293041)

  • 61. The relative contributions of ecstasy and cannabis to cognitive impairment.
    Croft RJ; Mackay AJ; Mills AT; Gruzelier JG
    Psychopharmacology (Berl); 2001 Jan; 153(3):373-9. PubMed ID: 11271410
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination.
    Hysek CM; Simmler LD; Schillinger N; Meyer N; Schmid Y; Donzelli M; Grouzmann E; Liechti ME
    Int J Neuropsychopharmacol; 2014 Mar; 17(3):371-81. PubMed ID: 24103254
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Severe ketoacidosis complicated by 'ecstasy' ingestion and prolonged exercise.
    Seymour HR; Gilman D; Quin JD
    Diabet Med; 1996 Oct; 13(10):908-9. PubMed ID: 8911787
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans.
    Gerra G; Zaimovic A; Ferri M; Zambelli U; Timpano M; Neri E; Marzocchi GF; Delsignore R; Brambilla F
    Biol Psychiatry; 2000 Jan; 47(2):127-36. PubMed ID: 10664829
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Substance usage intention does not affect attentional bias: implications from Ecstasy/MDMA users and alcohol drinkers.
    Wilcockson TDW; Pothos EM; Parrott AC
    Addict Behav; 2019 Jan; 88():175-181. PubMed ID: 30205257
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Oxytocin, cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of recreational 'ecstasy'.
    Parrott AC
    Behav Pharmacol; 2016 Dec; 27(8):649-658. PubMed ID: 27681116
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users.
    Parrott AC
    Neuropsychobiology; 2009; 60(3-4):148-58. PubMed ID: 19893332
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users.
    Hanson KL; Luciana M; Sullwold K
    Drug Alcohol Depend; 2008 Jul; 96(1-2):99-110. PubMed ID: 18384979
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Subacute effects of ecstasy on mood: an exploration of associated risk factors.
    Scott RM; Hides L; Allen JS; Lubman DI
    J Psychopharmacol; 2013 Jan; 27(1):53-61. PubMed ID: 23095244
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Greater sexual risk-taking in female and male recreational MDMA/ecstasy users compared with alcohol drinkers: a questionnaire study.
    May AL; Parrott AC
    Hum Psychopharmacol; 2015 Jul; 30(4):272-5. PubMed ID: 26216562
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.
    Liechti ME; Vollenweider FX
    J Psychopharmacol; 2000; 14(3):269-74. PubMed ID: 11106307
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health.
    Verheyden SL; Maidment R; Curran HV
    J Psychopharmacol; 2003 Dec; 17(4):371-8. PubMed ID: 14870948
    [TBL] [Abstract][Full Text] [Related]  

  • 73. 3,4-methylenedioxyamfetamine (ecstasy) use reduces cognition.
    Chummun H; Tilley V; Ibe J
    Br J Nurs; 2010 Jan 28-Feb 10; 19(2):94-100. PubMed ID: 20235382
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Decreased pain tolerance and mood in recreational users of MDMA.
    O'Regan MC; Clow A
    Psychopharmacology (Berl); 2004 May; 173(3-4):446-51. PubMed ID: 14752588
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cognitive performance amongst recreational users of "ecstasy".
    Rodgers J
    Psychopharmacology (Berl); 2000 Jul; 151(1):19-24. PubMed ID: 10958112
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes.
    Parrott AC; Lock J; Conner AC; Kissling C; Thome J
    Neuropsychobiology; 2008; 57(4):165-80. PubMed ID: 18654086
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of (+/-) 3,4-methylene-dioxymethamphetamine (ecstasy) on dopamine system function in humans.
    Gerra G; Zaimovic A; Moi G; Giusti F; Gardini S; Delsignore R; Laviola G; Macchia T; Brambilla F
    Behav Brain Res; 2002 Aug; 134(1-2):403-10. PubMed ID: 12191827
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations.
    Price LH; Ricaurte GA; Krystal JH; Heninger GR
    Arch Gen Psychiatry; 1989 Jan; 46(1):20-2. PubMed ID: 2562914
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users.
    Daumann J; Schnitker R; Weidemann J; Schnell K; Thron A; Gouzoulis-Mayfrank E
    Neuroreport; 2003 Oct; 14(15):1983-7. PubMed ID: 14561934
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The impact of recreational MDMA 'ecstasy' use on global form processing.
    White C; Edwards M; Brown J; Bell J
    J Psychopharmacol; 2014 Nov; 28(11):1018-29. PubMed ID: 25142406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.